A Phase 1 Study of Brentuximab Vedotin Combined With ABVD for Hodgkin Lymphoma
| Status: | Archived |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | January 2010 |
A Phase 1 Dose-Escalation Safety Study of Brentuximab Vedotin in Combination With ABVD as Frontline Therapy in Patients With Hodgkin Lymphoma
The purpose of this study is to assess the safety profile of brentuximab vedotin in
combination with ABVD in treatment-naive Stage IIa or IIb-IV Hodgkin lymphoma. It is a
phase 1, single-arm, open-label dose escalation study designed to define the MTD, PK,
immunogenicity and anti-tumor activity of brentuximab vedotin in combination with frontline
therapy.
We found this trial at
2
sites
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
Houston, Texas 77030
713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
Click here to add this to my saved trials